T. Rowe Price Investment Management
WGS icon

T. Rowe Price Investment Management’s GeneDx Holdings WGS Stock Holding History

T. Rowe Price Investment Management’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-86,082
Closed -$5.53M – 805
2026
Q1 		$5.53M Sell
86,082
-498,068
-85% -$45.4M ﹤0.01% 560
2025
Q4 		$76M Sell
584,150
-133,853
-19% -$18.4M 0.05% 292
2025
Q3 		$77.4M Sell
718,003
-319,113
-31% -$34.8M 0.05% 311
2025
Q2 		$95.7M Buy
1,037,116
+533,383
+106% +$41.9M 0.06% 287
2025
Q1 		$44.6M Buy
+503,733
New +$43.7M 0.03% 417

Other funds holding WGS

CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

T. Rowe Price Investment Management's WGS Position: Q2 2026 in Review

T. Rowe Price Investment Management sold out of GeneDx Holdings (WGS) in Q2 2026, closing a stake of 86,082 shares — an estimated $5.53M sold.

T. Rowe Price Investment Management first reported a position in WGS in Q1 2025 and held it in 5 quarters. The position peaked at $95.7M in Q2 2025. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

  • T. Rowe Price Investment Management reported no remaining GeneDx Holdings position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 86,082 GeneDx Holdings shares in Q2 2026, an estimated $5.53M.
  • T. Rowe Price Investment Management first reported a position in GeneDx Holdings in Q1 2025 and held it in 5 quarters.
  • T. Rowe Price Investment Management's GeneDx Holdings position peaked at $95.7M in Q2 2025.
  • 223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.